Faculty
Sairah Ahmed, MD
Associate Professor
Department of Lymphoma/Myeloma
Director of CART Program
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ann S. LaCasce, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director
Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
Boston, Massachusetts
John P. Winters III, MD
Hematology/Oncology Physician
New England Cancer Specialists
Scarborough, Maine
Target Audience
The educational design of this activity addresses the needs of hematologists/oncologists related to the treatment of B-cell non-Hodgkin lymphoma (NHL).
Program Overview
Community hematologist/oncologists (hem-oncs) are tasked with staying up to date on the latest clinical trial data across multiple oncologic disease states, which typically entails proficiency with rapidly changing management guidelines. During two of the largest global hem-onc conferences, American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Hybrid Congress, data were presented that highlight new findings and treatment updates in patients with non-Hodgkin lymphoma (NHL). Our expert hem-onc faculty, Drs. Sairah Ahmed and Ann LaCasce, distill the pivotal clinical trial data across diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and other subtypes of NHL (eg, marginal zone lymphoma) and answer practice-based questions from their community hem-onc colleagues.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the newer US Food and Drug Administration–approved therapies in various non-Hodgkin lymphoma subtypes
- Summarize the most recent clinical trial data on investigational therapies in non-Hodgkin lymphoma, emerging from recent hematology/oncology conferences
- Discuss approaches to implementation of new findings and therapeutic options in non-Hodgkin lymphoma therapies